Cart
sales@molnova.com
c-Met inhibitor 1
CAS No. 1357072-61-7
c-Met inhibitor 1( —— )
Catalog No. M22126 CAS No. 1357072-61-7
c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 164 | In Stock |
|
| 10MG | 224 | In Stock |
|
| 25MG | 376 | In Stock |
|
| 50MG | 557 | In Stock |
|
| 100MG | 795 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namec-Met inhibitor 1
-
NoteResearch use only, not for human use.
-
Brief Descriptionc-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.
-
Descriptionc-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
Recptorc-Met
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1357072-61-7
-
Formula Weight362.41
-
Molecular FormulaC17H14N8S
-
Purity>98% (HPLC)
-
SolubilityDMSO:18 mg/mL (49.67 mM; Need ultrasonic)
-
SMILESCn1cc(cn1)-c1ccc2nnc(Sc3ccc4nn(C)cc4c3)n2n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. PCT Int. Appl. (2012), WO 2012015677 A1 20120202.
molnova catalog
related products
-
Cabozantinib hydroch...
Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2 c-Met Kit Axl and Flt4 (IC50s: 0.035 1.3 4.6 7 and 6 nM).
-
Hepln-13
Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
-
Ningetinib
Ningetinib (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
